HIF-1 and hypoxic response: The plot thickens

Current Opinion in Genetics and Development

Volumn 14, Issue 1, 2004, Pages 81-85

  Poellinger, Lorenz ^a   Johnson, Randall S ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE TRANSCRIPTION FACTOR 1; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

CARCINOGENESIS; DEVELOPMENT; DRUG MECHANISM; ERYTHROPOIESIS; HUMAN; HYPOXIA; NONHUMAN; OXYGEN TENSION; OXYGENATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MODIFICATION; PULMONARY HYPERTENSION; REGULATORY MECHANISM; REVIEW;

ANIMALIA;

EID: 0842303171     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gde.2003.12.006     Document Type: Review

References (45)

1. Wang G.L., Semenza G.L. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem. 270:1995;1230-1237.
2. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA. 95:1998;7987-7992.
3. Maxwell P.H., Wiesener M.S., Chang G.W., Clifford S.C., Vaux E.C., Cockman M.E., Wykoff C.C., Pugh C.W., Maher E.R., Ratcliffe P.J. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 399:1999;271-275.
4. Cockman M., Masson N., Mole D., Jaakkola P., Chang G., Clifford S., Maher E., Pugh C., Ratcliffe P., Maxwell P. Hypoxia inducible factor alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem. 275:2000;25733-25741.
5. Kamura T., Sato S., Iwai K., Czyzyk-Krzeska M., Conaway R.C., Conaway J.W. Activation of HIF1alpha ubiquitination by a reconstituted von Hippel- Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci USA. 97:2000;10430-10435.
6. Ohh M., Park C.W., Ivan M., Hoffman M.A., Kim T.Y., Huang L.E., Pavletich N., Chau V., Kaelin W.G. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol. 2:2000;423-427.
7. Tanimoto K., Makino Y., Pereira T., Poellinger L. Mechanism of regulation of the HIF-1α by the von Hippel-Lindau tumor suppressor protein. EMBO J. 19:2000;4298-4309.
8. Yu F., White S.B., Zhao Q., Lee F.S. HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc Natl Acad Sci USA. 98:2001;9630-9635.
9. 2-regulated prolyl hydroxylation. Science. 292:2001;468-472.
10. 2 sensing. Science. 292:2001;464-468.
11. Epstein A.C., Gleadle J.M., McNeill L.A., Hewitson K.S., O'Rourke J., Mole D.R., Mukherji M., Metzen E., Wilson M.I., Dhanda A.et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell. 107:2001;43-54.
12. Bruick R.K., McKnight S.L. A conserved family of prolyl-4-hydroxylases that modify HIF. Science. 294:2001;1337-1340.
13. Berra E., Benizri E., Ginouves A., Volmat V., Roux D., Pouyssegur J. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J. 22:2003;4082-4090.
14. Lando D., Peet D.J., Whelan D.A., Gorman J.J., Whitelaw M.L. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science. 295:2002;858-861.
15. Mahon P.C., Hirota K., Semenza G.L. FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 15:2001;2675-2686 Crucial papers that discuss the determination of a novel means of regulating the HIF response.
16. Hewitson K.S., McNeill L.A., Riordan M.V., Tian Y.M., Bullock A.N., Welford R.W., Elkins J.M., Oldham N.J., Bhattacharya S., Gleadle J.M.et al. Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family. J Biol Chem. 277:2002;26351-26355.
17. Makino Y., Cao R., Svensson K., Bertilsson G., Åsman M., Tanaka H., Cao Y., Berkenstam A., Poellinger L. Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature. 414:2001;550-554.
18. Makino Y., Kanopka A., Wilson W.J., Tanaka H., Poellinger L. IPAS is an hypoxia-inducible splicing variant of the HIF-3α locus. J Biol Chem. 277:2002;32405-32408.
19. Jeong J.W., Bae M.K., Ahn M.Y., Kim S.H., Sohn T.K., Bae M.H., Yoo M.A., Song E.J., Lee K.J., Kim K.W. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell. 111:2002;709-720 This study demonstrates an interesting mechanism of HIF-1 regulation outside of the hydroxylase axis.
20. Wang G.L., Semenza G.L. Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia. J Biol Chem. 268:1993;21513-21518.
21. Ang S.O., Chen H., Hirota K., Gordeuk V.R., Jelinek J., Guan Y., Liu E., Sergueeva A.I., Miasnikova G.Y., Mole D.et al. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet. 32:2002;614-621 A novel and exciting link to a disease of the oxygen delivery system, namely, the erythrocytes.
22. Grimm C., Wenzel A., Groszer M., Mayser H., Seeliger M., Samardzija M., Bauer C., Gassmann M., Reme C.E. HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration. Nat Med. 8:2002;718-724 A fascinating demonstration of the role of EPO in protecting against light-induced injury.
23. Morita M., Ohneda O., Yamashita T., Takahashi S., Suzuki N., Nakajima O., Kawauchi S., Ema M., Shibahara S., Udono T.et al. HLF/HIF-2alpha is a key factor in retinopathy of prematurity in association with erythropoietin. EMBO J. 22:2003;1134-1146.
24. Tian H., Hammer R.E., Matsumoto A.M., Russell D.W., McKnight S.L. The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development. Genes Dev. 12:1998;3320-3324.
25. Peng J., Zhang L.Y., Drysdale L., Fong G.H. The transcription factor EPAS-1/hypoxia-inducible factor 2 alpha plays an important role in vascular remodeling. Proc Natl Acad Sci USA. 97:2000;8386-8391.
26. Compernolle V., Brusselmans K., Acker T., Hoet P., Tjwa M., Beck H., Plaisance S., Dor Y., Keshet E., Lupu F.et al. Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat Med. 8:2002;702-710.
27. •] present the major and varied findings following the deletion of HIF-2α in mice.
28. Brusselmans K., Compernolle V., Tjwa M., Wiesener M.S., Maxwell P.H., Collen D., Carmeliet P. Heterozygous deficiency of hypoxia-inducible factor-2alpha protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia. J Clin Invest. 111:2003;1519-1527.
29. Tanimoto K., Yoshiga K., Eguchi H., Kaneyasu M., Ukon K., Kumazaki T., Oue N., Yasui W., Imai K., Nakachi K.et al. Hypoxia-inducible factor-1{alpha} polymorphisms associated with enhanced transactivation capacity, implying clinical significance. Carcinogenesis. 24:2003;1779-1783 An interesting finding with broad significance, indicating that different HIF-1α polymorphisms might confer differing degrees of susceptibility to cancer.
30. Sowter H.M., Raval R., Moore J., Ratcliffe P.J., Harris A.L. Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia. Cancer Res. 63:2003;6130-6134.
31. •] demonstrate the primacy of HIF-1α relative to HIF-2α function in hypoxic response.
32. Scortegagna M, Ding K, Oktay Y, Gaur A, Thurmond F, Yan LJ, Marck BT, Matsumoto AM, Shelton JM, Richardson JA et al.: Multiple organ pathology, metabolic abnormalities and impaired homeostasis of reactive oxygen species in Epas1(-/-) mice. Nat Genet 2003, in press.
33. Seagroves T.N., Hadsell D., McManaman J., Palmer C., Liao D., McNulty W., Welm B., Wagner K.U., Neville M., Johnson R.S. HIF1alpha is a critical regulator of secretory differentiation and activation, but not vascular expansion, in the mouse mammary gland. Development. 130:2003;1713-1724.
34. Yun Z., Maecker H.L., Johnson R.S., Giaccia A.J. Inhibition of PPAR gamma 2 gene expression by the HIF-1-regulated gene DEC1/Stra13: a mechanism for regulation of adipogenesis by hypoxia. Dev Cell. 2:2002;331-341.
35. Jogi A., Ora I., Nilsson H., Lindeheim A., Makino Y., Poellinger L., Axelson H., Pahlman S. Hypoxia alters gene expression in human neuroblastoma cells toward an immature and neural crest-like phenotype. Proc Natl Acad Sci USA. 99:2002;7021-7026.
36. Tomita S., Ueno M., Sakamoto M., Kitahama Y., Ueki M., Maekawa N., Sakamoto H., Gassmann M., Kageyama R., Ueda N.et al. Defective brain development in mice lacking the Hif-1alpha gene in neural cells. Mol Cell Biol. 23:2003;6739-6749.
37. Cramer T., Yamanishi Y., Clausen B.E., Forster I., Pawlinski R., Mackman N., Haase V.H., Jaenisch R., Corr M., Nizet V.et al. HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell. 112:2003;645-657 The first demonstration that HIF-1 is a primary factor in inflammation.
38. Schioppa T., Uranchimeg B., Saccani A., Biswas S.K., Doni A., Rapisarda A., Bernasconi S., Saccani S., Nebuloni M., Vago L.et al. Regulation of the Chemokine receptor CXCR4 by Hypoxia. J Exp Med. 198:2003;1391-1402.
39. •] implicate HIF-1 in targeting metastatic tumor cells to new tissues through the CXCR4 chemokine receptor.
40. Muller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., McClanahan T., Murphy E., Yuan W., Wagner S.N.et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 410:2001;50-56.
41. Blouw B., Song H., Tihan T., Bosze J., Ferrara N., Gerber H.P., Johnson R.S., Bergers G. The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell. 4:2003;133-146 A demonstration that hypoxic response can regulate tumor behavior in a tissue- and site-dependent fashion.
42. Mandriota S.J., Turner K.J., Davies D.R., Murray P.G., Morgan N.V., Sowter H.M., Wykoff C.C., Maher E.R., Harris A.L., Ratcliffe P.J.et al. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell. 1:2002;459-468.
43. Mack F.A., Rathmell W.K., Arsham A.M., Gnarra J., Keith B., Simon M.C. Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth. Cancer Cell. 3:2003;75-88.
44. Kondo K., Klco J., Nakamura E., Lechpammer M., Kaelin W.G. Jr. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell. 1:2002;237-246.
45. Maranchie J.K., Vasselli J.R., Riss J., Bonifacino J.S., Linehan W.M., Klausner R.D. The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell. 1:2002;247-255.